Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells $525,800.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $35,583,199.52. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Helen Torley also recently made the following trade(s):

• On Wednesday, September 25th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.34, for a total value of $563,400.00.
• On Tuesday, September 10th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $59.09, for a total transaction of $590,900.00.
• On Thursday, September 12th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded down $3.47 during trading on Wednesday, reaching $50.66. The company’s stock had a trading volume of 3,539,241 shares, compared to its average volume of 1,292,661. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $65.53. The stock has a 50-day moving average price of $58.90 and a two-hundred day moving average price of $50.61. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. The stock has a market capitalization of $6.45 billion, a P/E ratio of 21.02, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. During the same period in the prior year, the firm earned $0.68 earnings per share. Halozyme Therapeutics’s revenue was up 4.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Prudential PLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $1,248,000. Neo Ivy Capital Management acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $207,000. Virtu Financial LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $607,000. Congress Asset Management Co. MA raised its position in shares of Halozyme Therapeutics by 15.6% in the 4th quarter. Congress Asset Management Co. MA now owns 351,076 shares of the biopharmaceutical company’s stock valued at $12,976,000 after acquiring an additional 47,359 shares during the period. Finally, Wellington Management Group LLP raised its position in shares of Halozyme Therapeutics by 16.1% in the 4th quarter. Wellington Management Group LLP now owns 180,856 shares of the biopharmaceutical company’s stock valued at $6,684,000 after acquiring an additional 25,125 shares during the period. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. TD Cowen boosted their price target on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Morgan Stanley upped their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group lifted their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $58.00 to $62.00 in a research note on Monday. Finally, HC Wainwright reiterated a “buy” rating and set a $65.00 target price on shares of Halozyme Therapeutics in a research report on Friday, October 4th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.